Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
IOME BIO logo — Harnessing unique, proprietary microbiome insights to unlock...

IOME BIO

Harnessing unique, proprietary microbiome insights to unlock the efficacy of immuno-oncology

Founded 2020 France France 4 employees Biotechnology, Health Care +1

General Information

Company Name IOME BIO
Founded Year 2020
Location France France +1
Employees 4
Industries Biotechnology, Health Care, Life Sciences
Social

Get notified when IOME BIO moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About IOME BIO

Iome Bio is a biotechnology company based in France, founded in 2020. The company is focused on harnessing unique, proprietary microbiome insights to unlock the efficacy of immuno-oncology. With a slogan of "Harnessing unique, proprietary microbiome insights to unlock the efficacy of immuno-oncology," Iome Bio aims to address the challenge of low response rates to current cancer treatments, particularly PD/L-1 therapies. The company's differentiated approach involves targeting the microbiome's downstream mode of action, enabling signal amplification through first-in-class monoclonal antibodies. This approach sets Iome Bio apart from other companies in the field, which mostly focus on T-cells or the tumor microenvironment. The company's strategy aligns with the growing evidence that patients with healthier microbiomes respond better to immuno-oncology therapies. Considering the significant unmet need in cancer treatment and the promising clinical data related to enhancing the microbiome, Iome Bio's approach holds potential. While the company has not disclosed its last investment or investors, the innovative nature of its approach and the pressing demand for improved cancer therapies position Iome Bio as a compelling prospect for future investment and a noteworthy player in the biotechnology and healthcare industries.

Taxonomy: microbiome insights, immuno-oncology, PD/L-1 therapies, cancer treatment, R&D programs, live biotherapeutics, monoclonal antibodies, French biotech company, immuno-oncology drugs, checkpoint inhibitors, tumor microenvironment, drug resistance, Harvard laboratories, first in class, clinical data

No funding data available for IOME BIO yet.

Get notified when IOME BIO raises funding

IOME BIO Alternatives & Competitors

IOME BIO vs
NextCure, Inc.
NextCure, Inc. United States

NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel...

Post Ipo Equity
49 employees
Biopharma, Biotechnology
IOME BIO vs
ALX Oncology
ALX Oncology United States

ALX Oncology is a clinical-stage biotechnology company advancing cancer therapies by boosting the im...

IPO
63 employees
Biopharma, Biotechnology
IOME BIO vs
Imugene Limited
Imugene Limited Australia

Bringing Effective New Treatments And Options To Patients Who Need Them

IPO
29 employees
Biotechnology, Health Care

FAQ About IOME BIO

Harnessing unique, proprietary microbiome insights to unlock the efficacy of immuno-oncology
IOME BIO was founded in 2020.
IOME BIO is headquartered in France.
IOME BIO operates in the following industries: Biotechnology, Health Care, Life Sciences.
IOME BIO has approximately 4 employees.
Top alternatives and competitors to IOME BIO include NextCure, Inc., ALX Oncology, Imugene Limited, Oxford BioTherapeutics, TME Pharma. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
IOME BIO and NextCure, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors IOME BIO and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy